Related Experiment Video
Updated: Aug 7, 2026

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
Published on: December 16, 2016
Reprogramming FGFR isoform specificity in FGF2 by deep mutational scanning
Yuga Okada1, Jumpei Morimoto1, Shinsuke Sando1,2
1Department of Chemistry and Biotechnology, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-8656 Japan ssando@chembio.t.u-tokyo.ac.jp.
Abstract:
The fibroblast growth factor (FGF) family exhibits distinct yet overlapping specificities toward seven fibroblast growth factor receptor (FGFR) isoforms, forming highly complex signaling networks through broad binding and activation profiles. FGF2 plays important physiological roles and has considerable therapeutic potential; however, its pleiotropic and non-selective activation of FGFRs can lead to adverse effects. Therefore, molecular engineering of FGF ligands with controlled receptor isoform specificity is required. Here, we engineered FGF2 variants with altered FGFR isoform specificity using mRNA display-based deep mutational scanning (DMS), thereby enabling systematic evaluation of residues within the FGFR-binding interface that contribute to FGFR isoform specificity despite limited structural information. We demonstrate for the first time that FGFs with altered FGFR isoform specificity can be generated. Notably, FGFR isoform specificity proved malleable and could be reprogrammed by single-amino acid substitutions. These findings reveal that receptor selectivity in FGF2 is tunable and provide a framework for rationally designing FGF ligands with tailored FGFR isoform specificity, advancing the understanding and control of complex FGF/FGFR signaling networks.
Insights
Researchers engineered fibroblast growth factor 2 (FGF2) variants with altered fibroblast growth factor receptor (FGFR) specificity. Single-amino acid changes successfully reprogrammed receptor selectivity, enabling tailored FGF/FGFR signaling network control.
Area of Science:
- Molecular biology
- Biochemistry
- Signaling pathways
Background:
- The fibroblast growth factor (FGF) family and its seven fibroblast growth factor receptor (FGFR) isoforms form complex signaling networks.
- FGF2 has significant physiological roles and therapeutic potential, but its broad FGFR activation causes adverse effects.
- Engineering FGF ligands for controlled FGFR isoform specificity is crucial for therapeutic applications.
Purpose of the Study:
- To engineer FGF2 variants with altered FGFR isoform specificity.
- To identify key residues in the FGFR-binding interface that determine receptor specificity.
- To establish a framework for designing FGF ligands with tailored specificity.
Main Methods:
- Utilized mRNA display-based deep mutational scanning (DMS) to engineer FGF2 variants.
- Systematically evaluated residues within the FGFR-binding interface.
- Assessed the FGFR isoform specificity of engineered FGF2 variants.
Main Results:
- Successfully generated FGF2 variants with altered FGFR isoform specificity.
- Demonstrated that FGFR isoform specificity is malleable and can be reprogrammed.
- Identified single-amino acid substitutions as sufficient to alter receptor selectivity.
Conclusions:
- Receptor selectivity in FGF2 is tunable.
- Provided a method for rationally designing FGF ligands with specific FGFR isoform targeting.
- Advanced the understanding and control of FGF/FGFR signaling networks.

